Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IAPP | P10997 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5552029 | 0.98 | KDM4E (0.45) | TDP1KDM4ELMNAALDH1A1TSHR | |
| SCHEMBL27577356 | 0.86 | TSHR (0.42) | TDP1KDM4ELMNAALDH1A1TSHR | |
| SCHEMBL3486169 | 0.84 | DGKA (0.42) | TDP1LMNAALDH1A1TSHRCYP1A2 | |
| SCHEMBL6233402 | 0.84 | KDM4E (0.42) | KDM4ELMNATSHRHTR2C | |
| SCHEMBL468549 | 0.81 | TSHR (0.44) | KDM4ELMNAALDH1A1TSHRCYP1A2 | |
| SCHEMBL619312 | 0.78 | TDP1 (0.69) | TDP1KDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL27624661 | 0.77 | ALDH1A1 (0.55) | TDP1KDM4ELMNAALDH1A1TSHR | |
| SCHEMBL765093 | 0.77 | TSHR (0.68) | TDP1KDM4ELMNAALDH1A1TSHR | |
| SCHEMBL2230276 | 0.76 | KMT2A (0.55) | TDP1LMNAALDH1A1TSHRHTR2C | |
| SCHEMBL24219 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-118103040-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11701347-B2 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-18 | — | — | US | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20210015806-A1 | USE OF 5-FLUORO-4-(4-FLUORO-2-METHOXYPHENYL)-N-{4-[(S-METHYLSULFONIMIDOYL)METHYL]PYRIDIN-2-YL}PYRIDIN-2-AMINE FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| CN-107787320-B | Protein targeting compounds, compositions, methods and uses thereof | 拜欧赛里克斯公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3607299-A1 | OPTOFLUIDIC DEVICE AND METHOD FOR DETECTING CIRCULATING TUMOUR CELLS | Universitat Rovira i Virgili (ES) | 2020-02-12 | — | — | EP | disclosed |
| CN-104508486-B | Method for determining breast cancer-associated disease state and array for use in the method | 伊缪诺维亚公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109406483-A | A method of 5-ALA is detected using SERS | 福建师范大学 | 2019-03-01 | — | — | CN | disclosed |
| WO-2013084061-A1 | COMPOSITIONS FOR PHOTODYNAMIC THERAPY CHEMICALLY MODIFIED TO INCREASE EPITHELIA PENETRATION AND CELLULAR BIOAVAILABILITY | Yagna Limited (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013059738-A2 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| CN-102985557-A | Methods and compositions for cell proliferation-related disorders | AGIOS PHARMACEUTICALS INC | 2013-03-20 | — | — | CN | disclosed |
| CN-102985044-A | System for opening medical blister packs | FUTURELOGIX APS | 2013-03-20 | — | — | CN | disclosed |
| WO-2013019681-A2 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011071892-A2 | SURFACES FOR CONTROLLED BIOADHESION, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| CN-101500649-A | A device for and a method of activating a physiologically effective substance by ultrasonic waves, and a capsule | KONINKL PHILIPS ELECTRONICS NV (NL) | 2009-08-05 | — | — | CN | disclosed |
| EP-2051776-A2 | A DEVICE FOR AND A METHOD OF ACTIVATING A PHYSIOLOGICALLY EFFECTIVE SUBSTANCE BY ULTRASONIC WAVES, AND A CAPSULE | Koninklijke Philips Electronics N.V. (NL) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008018019-A2 | A DEVICE FOR AND A METHOD OF ACTIVATING A PHYSIOLOGICALLY EFFECTIVE SUBSTANCE BY ULTRASONIC WAVES, AND A CAPSULE | KONINKLIJKE PHILIPS ELECTRONICS N. V. (NL) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701347-B2 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma | BCL6, MYC, BCL6B | TDP1 1527/4885KDM4E 48/4885LMNA 327/4885 |
| US-20210015806-A1 | USE OF 5-FLUORO-4-(4-FLUORO-2-METHOXYPHENYL)-N-{4-[(S-METHYLSULFONIMIDOYL)METHYL]PYRIDIN-2-YL}PYRIDIN-2-AMINE FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BCL6, MYC, BCL6B | TDP1 1527/4885KDM4E 48/4885LMNA 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.